How Small a Trace Can a New Quantum Biosensor Actually Detect?
Exploring the Next Generation of Ultra-Sensitive Detection Technologies in Forensic Science
Imagine a crime scene where investigators recover only a handful of invisible biological molecules — too little for gas chromatography, too degraded for standard PCR. Could a new class of quantum-enabled biosensors detect evidence that today's forensic instruments would simply miss? This editorial examines what the peer-reviewed record actually shows, and what remains laboratory promise rather than courtroom reality.
1. Introduction: The Molecule Too Small to Miss
Every forensic investigator eventually confronts the same frustrating limit: the sample is real, the crime is real, but the trace left behind is simply too small for the instrument in front of them. A degraded touch-DNA swab. A trace of an explosive precursor on a fingertip, long since washed away. A few nanograms of a novel psychoactive substance dried into carpet fibre. Conventional forensic instrumentation — polymerase chain reaction (PCR), gas chromatography-mass spectrometry (GC-MS), enzyme-linked immunosorbent assay (ELISA) — has served the discipline well for decades, but each technique has a sensitivity floor beneath which evidence effectively becomes invisible.
Quantum biosensors are being developed precisely to push past that floor. By exploiting quantum-mechanical phenomena — electron spin coherence, plasmon resonance, single-photon emission, and quantum confinement in nanomaterials — researchers are reporting detection limits that were unthinkable a decade ago: attomolar and zeptomolar nucleic acid concentrations, single-digit molecule counts, and even genuine single-molecule optical signatures. The scientific question this editorial sets out to answer is not whether quantum biosensors sound impressive — they do — but how small a trace they can actually and reliably detect today, which forensic evidence types stand to benefit, and how far this technology still is from a validated, court-admissible forensic tool.
2. Why Detecting Tiny Traces Matters in Forensic Science
Forensic science rests on Locard's Exchange Principle — the idea that every contact between a perpetrator and a crime scene leaves a mutual exchange of material, however microscopic. In practice, that exchange is often at the very edge of detectability: a few skin cells transferred by a fleeting touch, a nanogram-scale residue of an accelerant, a trace metabolite in a degraded biological fluid. The gap between what Locard's principle predicts should be present and what conventional instruments can actually confirm is where cases stall.
Conventional analytical methods each carry an inherent sensitivity ceiling. PCR requires a minimum number of intact target DNA copies and can be defeated by severe degradation or inhibitors. GC-MS and LC-MS/MS need sufficient sample volume and often destroy the sample during analysis. ELISA-based immunoassays are limited by antibody-antigen binding kinetics and typically plateau in the picomolar-to-nanomolar range. When trace evidence falls below these thresholds, it is not that the evidence isn't there — it is that current instruments cannot reliably distinguish signal from background noise. This is precisely the gap quantum-enhanced sensing aims to close, because quantum systems can, in principle, approach or reach the fundamental physical limit of detection: a single molecule.
DEFINITION
Limit of Detection (LOD): the lowest concentration or quantity of an analyte that an analytical method can reliably distinguish from background noise, typically expressed in molarity (M) or absolute molecule count. Molar scale, from largest to smallest concentration: millimolar (mM) → micromolar (µM) → nanomolar (nM) → picomolar (pM) → femtomolar (fM) → attomolar (aM) → zeptomolar (zM). One attomolar in a microlitre sample corresponds to roughly 0.6 molecules; most attomolar-range biosensor claims refer to bulk solution concentration rather than a literal single molecule in the test volume.
3. What Is a Quantum Biosensor?
A quantum biosensor is an analytical device that couples a biological recognition element — an antibody, aptamer, DNA probe, enzyme, or CRISPR guide RNA — to a quantum-mechanical transducer, so that a biomolecular binding or reaction event produces a measurable change in a quantum property such as electron spin state, photon emission statistics, or plasmon resonance frequency. Researchers writing in ECS Sensors Plus describe quantum biosensors as originating at the intersection of physics and biosensing, exploiting quantum phenomena to amplify sensitivity, specificity, and detection speed relative to conventional biosensors by fusing biological entities such as DNA, proteins, or enzymes with quantum sensors that produce detectable changes in light emission when they interact with sample molecules.
A typical quantum biosensor architecture has four components:
- Recognition element: the biological or chemical layer that binds the target analyte selectively (antibody, aptamer, ssDNA probe, CRISPR-Cas complex).
- Quantum transducer: the physical component that undergoes a measurable quantum-level change on binding — a nitrogen-vacancy (NV) diamond centre, a semiconductor quantum dot, a plasmonic nanostructure, or a single-photon detector array.
- Signal readout system: optical, electrical, or magnetic instrumentation that converts the quantum-level change into a usable signal (fluorescence intensity, current shift, Raman spectrum, spin relaxation time).
- Data interpretation layer: increasingly machine-learning assisted, used to extract meaningful signal from single-molecule stochastic noise (blinking, spectral fluctuation) that is characteristic of quantum-scale measurement.
The defining difference from a conventional biosensor is not the biological recognition step — that part is often identical — but the transduction step. Conventional biosensors (electrochemical, standard fluorescence, basic SPR) rely on classical, ensemble-averaged signals that require a statistically significant population of bound molecules to register above noise. Quantum biosensors exploit phenomena — spin coherence, quantum confinement, plasmonic near-field enhancement, or genuinely quantum states of light — that can, under the right conditions, register the presence of a single binding event.
4. The Science Behind Ultra-Sensitive Detection
Nitrogen-vacancy (NV) diamond centres. An NV centre is an atomic-scale point defect in diamond — a nitrogen atom next to a lattice vacancy — whose electron spin state can be optically initialised and read out at room temperature. Because the spin state is exquisitely sensitive to local magnetic noise, temperature, and chemical environment, NV centres can report on nanoscale biochemical events without requiring cryogenic cooling, which is a major practical advantage over many other quantum platforms. Reviews in Nature Reviews Physics describe how NV-diamond quantum sensors are now being adapted for biomedical sensing at the nanoscale including detection of free radicals, monitoring of drug efficacy in biological fluids, and quantum monitoring of cellular metabolic activity in single mitochondria. A frequently cited demonstration coupled NV-diamond magnetometry with CRISPR-generated magnetic tags to detect SARS-CoV-2 RNA, achieving a limit of detection of a few hundred RNA copies with under one percent false negatives — illustrating the nucleic-acid sensitivity this platform can reach outside a purely academic setting.
Quantum dots (QDs). Quantum dots are semiconductor nanocrystals a few nanometres across whose optical and electronic properties are governed by quantum confinement — the emission wavelength can be precisely tuned by particle size alone. This tunability enables multiplexed detection (multiple targets tagged with differently sized QDs, read out simultaneously) and exceptionally bright, photostable fluorescent tags compared with traditional organic dyes. Carbon quantum dots in particular are gaining forensic attention because of their tunable fluorescence and biocompatibility, with a 2025 review in RSC Advances describing their transformative possibilities in forensic science for addressing longstanding challenges in the detection, analysis, and preservation of trace evidence.
Surface-enhanced Raman spectroscopy (SERS) and plasmonics. When a target molecule sits within nanometres of a roughened noble-metal (gold or silver) nanostructure, the local electromagnetic field generated by collective electron oscillations — surface plasmons — can amplify the molecule's Raman scattering signal by factors of many orders of magnitude. This effect is powerful enough that SERS is one of the only spectroscopic techniques capable of detecting truly single molecules through their vibrational "fingerprint," a capability formally demonstrated as far back as 1997 and refined considerably since. A 2026 review characterises SERS as providing molecular fingerprinting with ultrahigh sensitivity while enabling single-molecule detection for forensic evidence that is trace-level and often degraded.
Graphene and 2D-material field-effect transistors (FETs). Graphene is a single atomic layer of carbon whose entire mass is essentially "surface," making it extraordinarily sensitive to any charge perturbation caused by a binding event on that surface. Functionalised with DNA probes or antibodies, graphene FET biosensors have demonstrated some of the lowest detection limits ever reported for nucleic acids and proteins, discussed in detail below.
CRISPR-based biosensing. CRISPR-Cas systems (Cas12a, Cas13a) exhibit a collateral cleavage property: once the guide RNA correctly binds its target sequence, the activated Cas enzyme indiscriminately cleaves nearby reporter probes, producing a strong, amplifiable signal from a single recognition event. Combined with fluorescent or Raman-active reporters, CRISPR platforms such as SHERLOCK and DETECTR have become a key building block for amplification-free or amplification-light nucleic-acid biosensors, including hybrid CRISPR-SERS platforms discussed in Section 5.
SCIENTIFIC INSIGHT
The shared thread across NV-diamond, quantum-dot, SERS, and graphene platforms is not a single "quantum trick," but a common strategy: amplify a physical signal so strongly at the nanoscale that the statistical noise floor drops below the signal generated by one, or a very small number of, target molecules. A review in Applied Physics Reviews frames this succinctly — quantum systems leverage quantum-mechanical properties to enable ultrasensitive measurements and high-resolution imaging, overcoming limitations that conventional techniques face due to the limited quantity and small size of biomolecules and low signal-to-noise ratios.
5. How Small a Trace Can Current Quantum Biosensors Detect?
The honest answer is: it depends heavily on the analyte, the platform, and whether the number quoted comes from a controlled buffer solution or a real biological matrix like blood, urine, or soil residue. Detection limits reported in buffer are routinely one to three orders of magnitude better than the same sensor operating in serum, saliva, or crime-scene debris, because of matrix interference, non-specific binding, and signal quenching. The table below summarises representative, peer-reviewed detection limits across major evidence categories.
| Evidence / Analyte Type | Platform | Reported Detection Limit | Matrix |
|---|---|---|---|
| DNA (ssDNA hybridisation) | Graphene field-effect transistor | ~25 attomolar, SNP-discriminating | Buffer solution |
| DNA (nucleic acid, absolute count) | Deformed graphene-channel FET | ~18 molecules (600 zeptomolar) in buffer; ~600 molecules (20 aM) in human serum | Buffer & human serum |
| DNA (short ssDNA, no amplification) | Graphene biosensor | ~1 attomolar | Buffer solution |
| Trace-level DNA (CRISPR-tagged) | CRISPR-Cas12a + SERS | 224 attomolar | Prepared sample |
| Viral RNA (SARS-CoV-2) | NV-diamond magnetometry + CRISPR magnetic tags | A few hundred RNA copies, <1% false negatives | Clinical sample |
| Protein biomarker (Aβ42 / Aβ40) | 3D graphene foam electrochemical aptasensor | 252 aM (Aβ42) / 395 aM (Aβ40) | Buffer / biofluid model |
| Single protein molecule | Surface-enhanced Raman spectroscopy (SERS) | Single-molecule regime (proof of concept) | Gold substrate, controlled solution |
| Drug of abuse (ketamine) | Electrochemical / optical biosensor | ~10 nanomolar, result in 30 seconds | Undiluted urine |
| Trace drug residue in biofluids | Portable SERS nanosensor | Ultrasensitive, sub-therapeutic range (NIJ-funded) | Postmortem/clinical biofluids |
| Explosive / nitro-group residue | SERS on plasmonic nanostructures | Trace / single-molecule sensitivity reported for select nitro compounds | Surface swab / solution |
| Organic gunshot residue (OGSR) | Portable Raman / SERS | Field-portable trace detection (compound-dependent) | Skin/surface swab |
Two important caveats belong alongside this table. First, "attomolar" and "zeptomolar" figures describe bulk solution concentration, not necessarily proof that a single molecule was individually resolved in every case — although several of the studies above (notably the 18-molecule graphene FET result and single-molecule SERS studies) do report genuine single-particle or single-event resolution. Second, essentially all of the ultra-low LOD figures above come from optimised laboratory buffer conditions; forensic-relevant matrices such as degraded touch-DNA, soil-contaminated residue, or postmortem fluid routinely push real-world sensitivity one to two orders of magnitude higher than the numbers quoted in the founding papers.
6. Forensic Applications
Crime scene investigation and touch DNA. Ultra-low-input DNA detection is the single most consequential potential application. Attomolar-sensitivity graphene and CRISPR-based platforms could, in principle, extract usable genetic signal from degraded or vanishingly small touch-DNA deposits that presently fail standard PCR amplification thresholds — though this remains largely a laboratory demonstration rather than a validated casework tool.
Forensic toxicology and drug detection. Portable SERS nanosensors developed with support from the U.S. National Institute of Justice are aimed specifically at ultrasensitive characterisation of drugs in human biofluids, with researchers noting the technology's potential to decrease the likelihood of false negatives that can become a barrier to criminal charging, particularly in postmortem toxicology where matrix effects create high risk of missed detections. Electrochemical and optical biosensors for drugs of abuse are similarly moving toward rapid, field-usable formats for roadside and custody settings.
Explosive and gunshot residue detection. SERS-based platforms on plasmonic gold or silver nanostructures are being explored for trace explosive and organic gunshot residue detection directly at a scene, offering a non-destructive, molecularly specific alternative to bulk swab-and-lab workflows.
Trace biological evidence and biomarkers. Attomolar protein biosensors developed for biomedical diagnostics (such as Alzheimer's biomarker detection) illustrate transferable sensitivity that could eventually support trace protein or peptide identification in body-fluid evidence, though such transfer requires forensic-specific validation.
Environmental, wildlife, and food-fraud forensics. The same ultrasensitive nucleic-acid and small-molecule detection principles are already being applied to environmental contaminant tracing, wildlife-crime species identification, and counterfeit-pharmaceutical or food-fraud analysis, all of which share the same "vanishingly small trace, needs high specificity" profile as crime scene evidence.
INVESTIGATOR'S NOTE
A higher limit of detection is not automatically good news for a case file. Ultrasensitive platforms are also more prone to detecting background contamination — trace DNA or residue that arrived through secondary or tertiary transfer rather than the act itself. As sensitivity increases, the interpretive burden on the analyst to distinguish "present" from "probative" increases in parallel.
7. Recent Research Breakthroughs (2023–2026)
The following table summarises representative peer-reviewed studies published between 2023 and 2026 that are directly relevant to forensic-adjacent ultra-sensitive detection.
| Study / Platform | Institution / Source | Target Analyte | Reported Result | Forensic Relevance |
|---|---|---|---|---|
| Quantum-grade nanodiamond NV sensors (ACS Nano, Dec 2024) | Okayama University, Japan (with Sumitomo Electric & NIQST) | Spin-based bioimaging / thermal & chemical sensing | Nanodiamonds with spin properties comparable to bulk diamond, longer spin relaxation, lower microwave power needs | Improves practicality of NV biosensing outside specialised labs |
| NV-diamond quantum relaxometry for biomolecular interactions | Multi-institutional (arXiv/PNAS-linked work) | Free radicals, drug efficacy, cellular metabolism | Nanoscale, real-time monitoring in single cells and biofluids under ambient conditions | Demonstrates room-temperature biosensing viability relevant to trace biological evidence |
| Attomolar graphene-foam electrochemical aptasensor | University of Plymouth (Biosensors, Dec 2025) | Amyloid-beta protein biomarkers | 252–395 attomolar LOD with 12-day operational stability | Template for ultrasensitive trace-protein biosensor design |
| CRISPR-Cas12a + SERS DNA biosensor | Reviewed in Forensic Science International: Genetics, Oct 2024 | Trace-level target DNA sequence | 224 attomolar detection limit | Directly framed by the authors as forensic DNA profiling application |
| Digital colloid-enhanced Raman spectroscopy | Published in Nature, 2024 (Bi et al.) | Single-molecule counting | Digital, count-based single-molecule Raman detection | Pushes SERS toward quantitative single-molecule forensic assays |
| Carbon quantum dot forensic review | RSC Advances, September 2025 | General trace evidence (fluorescent tagging, latent evidence) | Comprehensive synthesis/application review; scalable green synthesis routes | Signals CQDs moving from novelty to mainstream forensic nanomaterial |
| Portable SERS nanosensors for drug biofluid analysis | NIJ-funded study, Office of Justice Programs | Illicit and prescription drugs in biofluids | Ultrasensitive characterisation designed for portable Raman deployment | Explicitly aimed at postmortem and field forensic toxicology |
Current limitations flagged by the authors themselves across these studies include: reproducibility of nanoscale fabrication at commercial scale, sensitivity loss in complex biological or environmental matrices compared with clean buffer, and — for graphene and 2D-material platforms specifically — long-term device stability and batch-to-batch variability.
8. Quantum Biosensors vs Conventional Detection Technologies
| Criterion | PCR | GC-MS / LC-MS/MS | ELISA / Immunoassay | Quantum Biosensors (SERS, NV, Graphene, QD) |
|---|---|---|---|---|
| Typical sensitivity | Femtomolar range, needs intact template | Nanogram-to-picogram sample mass | Picomolar–nanomolar | Attomolar to single-molecule (lab conditions) |
| Speed | Hours (with amplification) | 30 min–hours, sample prep heavy | 1–several hours | Minutes to near real-time (platform dependent) |
| Portability | Lab-bound; portable versions emerging | Largely lab-bound; some portable GC-MS exist | Lab or point-of-care kits | Portable Raman/SERS units exist; NV and graphene mostly lab-stage |
| Sample preparation | Extraction, purification, amplification required | Extensive derivatisation/extraction | Moderate; antibody-dependent | Often label-free or minimal-prep; matrix interference remains an issue |
| Multiplexing | Possible (multiplex PCR) but limited | High, via chromatographic separation | Limited without arrays | High potential (QD size-tuning, SERS spectral fingerprints) |
| Cost per test | Moderate | High (instrument + operator) | Low–moderate | Currently high (specialised fabrication); falling with scale |
| Forensic validation status | Fully validated, court-accepted standard | Fully validated, court-accepted standard | Widely validated for screening | Largely unvalidated for forensic casework; research/pilot stage |
The comparison makes the current reality plain: quantum biosensors can already out-perform PCR, GC-MS, and ELISA on raw sensitivity in controlled conditions, and in several cases on speed and portability. What they overwhelmingly lack, and what PCR and GC-MS have decades of, is the accumulated body of validation, standardisation, and legal precedent that makes an analytical result usable as courtroom evidence.
RESEARCH UPDATE
CRISPR-Cas technology in forensic investigations was described in Forensic Science International: Genetics (2024) as demonstrating strong potential due to high accuracy and sensitivity, with the review authors framing DNA profiling and identification as likely to be among its most significant near-term forensic applications, potentially reducing the number of steps and the cost associated with traditional profiling workflows.
9. Challenges Preventing Routine Forensic Adoption
- Validation and reproducibility. Forensic laboratories operate under strict validation protocols (ISO/IEC 17025, SWGDAM-style guidelines) requiring extensive repeatability, reproducibility, and known-error-rate studies before a method can be used on casework. Most quantum biosensor results published to date are single-lab, proof-of-concept demonstrations, not multi-laboratory validation studies.
- Instrument cost and specialised infrastructure. NV-diamond magnetometry and high-end graphene FET fabrication currently require cleanroom-grade nanofabrication and specialised optical/microwave readout equipment well beyond typical crime laboratory budgets.
- Standardisation. There is presently no universally agreed reference material, calibration standard, or reporting format for "quantum biosensor LOD" comparable to the standardised metrics used in forensic DNA (e.g., minimum template guidelines) or toxicology (e.g., confirmatory cut-off concentrations).
- Laboratory accreditation. Accreditation bodies assess method, instrument, and analyst competency together; a genuinely novel transduction principle requires new accreditation pathways that do not yet broadly exist for quantum sensing platforms.
- Court admissibility. Novel scientific methods face admissibility scrutiny (Daubert-style standards in the U.S., analogous standards elsewhere) that examine peer review, known error rates, and general acceptance in the relevant scientific community — criteria quantum biosensing has not yet cumulatively satisfied for forensic use.
- Operator training. Interpreting single-molecule stochastic signal behaviour (spectral blinking, fluctuation statistics) requires a different skill set than reading a chromatogram or an electropherogram, and dedicated forensic training pathways do not yet exist at scale.
- Environmental interference and matrix effects. As noted in Section 5, real crime-scene matrices routinely degrade the exceptional LODs reported in clean-buffer laboratory conditions.
- Scalability. Moving from a hand-built academic prototype to a mass-manufacturable, quality-controlled forensic instrument is a substantial engineering and regulatory undertaking that few of the platforms discussed here have yet undergone.
WARNING
None of the detection-limit figures cited in this article should be read as forensic-grade, court-validated results. They are drawn from peer-reviewed research papers describing controlled laboratory demonstrations. Presenting a quantum biosensor's laboratory LOD as though it were an established forensic capability — without the accompanying validation studies — would misrepresent the current state of the science.
10. Future of Quantum Biosensors in Forensic Science
Portable forensic biosensors. The trajectory across SERS, graphene, and electrochemical platforms is clearly toward miniaturisation — handheld Raman units and wearable SERS patches are already being demonstrated for field drug and explosive screening, suggesting crime-scene-deployable quantum-adjacent sensing is a realistic near-term direction even where full "quantum" readout hardware (like NV magnetometers) remains lab-bound.
AI-assisted biosensing. Because single-molecule and quantum-sensor signals are inherently noisy and stochastic, machine-learning classification is increasingly used to extract reliable analyte identification from raw spectral or electrical data — a trend documented across recent SERS and graphene-biosensor literature and likely to become a standard, rather than optional, component of any future forensic quantum biosensing platform.
Lab-on-a-chip and microfluidic integration. Integrating quantum transducers with microfluidic sample handling could reduce the manual sample-preparation steps that currently limit field deployment, moving toward a "sample-to-answer" forensic device.
Wearable and real-time evidence screening. Early wearable SERS sensor research points toward continuous, non-invasive monitoring applications that could eventually extend to real-time field screening for law enforcement, though current work is concentrated in healthcare and environmental monitoring rather than forensic deployment.
Quantum-enhanced diagnostics as a feeder field. Much of the fastest-moving quantum biosensor research is funded and published for medical diagnostics (cancer biomarkers, Alzheimer's, infectious disease) rather than forensic science specifically. Forensic adoption is likely to continue arriving as a downstream transfer of medical and analytical-chemistry innovation rather than as forensic-science-first research — a pattern consistent with the history of PCR and mass spectrometry themselves.
FUTURE SCOPE
The most plausible five-to-ten-year pathway is incremental and application-specific: portable SERS units for on-scene drug and explosive screening reaching pilot deployment first, followed by CRISPR-SERS or CRISPR-graphene hybrid platforms for trace DNA screening as a triage tool ahead of confirmatory PCR — not as its replacement. Full NV-diamond forensic instrumentation remains the most laboratory-bound of the technologies discussed and the least likely to see near-term field deployment.
11. Myth vs Reality
REALITY: Higher sensitivity increases the chance of detecting a trace, but it does not resolve questions of relevance, contamination, or transfer mechanism — a more sensitive instrument can just as easily detect irrelevant background material as probative evidence.
REALITY: Almost all of the detection limits described in this article come from academic and pre-clinical research settings; validated deployment inside accredited forensic laboratories remains rare to nonexistent as of 2026.
REALITY: Detecting a single DNA molecule is a signal-detection achievement, not an identification one — genotyping and profile comparison against a reference sample still require sufficient genetic material and established interpretation standards.
REALITY: Any analytical method offered as forensic evidence is subject to admissibility scrutiny over peer review, known error rates, and acceptance within the relevant scientific community — criteria quantum biosensing platforms have not yet cumulatively met.
12. Key Takeaways
- Quantum biosensors exploit spin coherence, plasmon resonance, quantum confinement, and single-photon detection to push sensitivity toward, and in some cases to, the single-molecule limit.
- Peer-reviewed detection limits already reported include roughly 18–25 molecules of DNA and attomolar-to-zeptomolar concentrations for nucleic acids and select proteins, though almost always under optimised buffer conditions.
- SERS remains the most forensically mature quantum-adjacent platform, with genuine single-molecule detection demonstrated and portable field units already emerging for drug and explosive screening.
- NV-diamond quantum sensing offers room-temperature, nanoscale biochemical sensing but remains the most laboratory-bound platform for forensic purposes.
- No quantum biosensor platform discussed here has completed the multi-laboratory validation, standardisation, and legal-admissibility pathway required for routine forensic casework use as of 2026.
- The realistic near-term forensic role for quantum biosensors is triage and field-screening, supplementing — not replacing — validated confirmatory methods like PCR and GC-MS.
13. Frequently Asked Questions
What is a quantum biosensor?
Can quantum biosensors detect a single DNA molecule?
How sensitive are quantum biosensors compared with PCR?
Will quantum biosensors replace PCR or mass spectrometry in forensic labs?
Are quantum biosensors currently used in forensic laboratories?
What is the difference between a quantum biosensor and a conventional biosensor?
What is an NV-diamond quantum sensor?
Can quantum biosensors detect explosives?
Can quantum biosensors detect illicit drugs?
What is a quantum dot?
What is SERS and why is it important for forensic trace evidence?
Are graphene biosensors quantum devices?
What does attomolar mean?
How does CRISPR technology work as a biosensor?
What is the CRISPR-SERS detection limit for DNA?
Can quantum biosensors detect degraded or touch DNA?
Why aren't quantum biosensors used in court yet?
What are the biggest technical limitations of quantum biosensors?
Do quantum biosensors need cryogenic cooling?
What forensic evidence types benefit most from quantum biosensors?
Can quantum biosensors be used at a crime scene, not just in a lab?
What is the role of artificial intelligence in quantum biosensing?
Are quantum biosensors expensive?
What is single-molecule detection and why does it matter forensically?
What breakthroughs occurred in quantum biosensing between 2023 and 2026?
14. Glossary
Attomolar (aM): a concentration unit equal to 10⁻¹⁸ moles per litre.
CRISPR-Cas: a bacterial-derived gene-editing and molecular-recognition system (Cas9, Cas12a, Cas13a) repurposed for highly specific nucleic-acid biosensing via guide-RNA target recognition and, in Cas12a/Cas13a, collateral cleavage signal amplification.
DETECTR / SHERLOCK: two widely used CRISPR-based nucleic-acid detection platforms exploiting Cas12a and Cas13a collateral cleavage activity respectively.
Field-effect transistor (FET) biosensor: a biosensor design in which analyte binding at a functionalised surface (e.g., graphene) alters the electrical current flowing through the transistor channel.
Graphene: a single atomic layer of carbon atoms arranged in a hexagonal lattice, valued in biosensing for its extremely high surface-to-volume ratio and electronic sensitivity to surface charge changes.
Limit of Detection (LOD): the lowest quantity or concentration of an analyte that a method can reliably distinguish from background noise.
Locard's Exchange Principle: the forensic science axiom that every contact between two entities results in a mutual transfer of material.
Nitrogen-vacancy (NV) centre: an atomic-scale defect in diamond consisting of a substitutional nitrogen atom adjacent to a lattice vacancy, whose optically readable electron spin state enables room-temperature quantum sensing.
Plasmon / Plasmonics: the collective oscillation of free electrons at a metal nanostructure's surface in response to light, which can locally concentrate and enhance electromagnetic fields.
Quantum confinement: the phenomenon by which the electronic and optical properties of a semiconductor nanocrystal (quantum dot) become size-dependent once the crystal is small enough to constrain electron behaviour.
Quantum dot (QD): a semiconductor nanocrystal, typically a few nanometres across, with size-tunable fluorescent emission.
Single-molecule detection (SMD): the capability of an analytical method to register the presence of one individual target molecule rather than requiring an ensemble-averaged population.
Surface-enhanced Raman spectroscopy (SERS): a spectroscopic technique in which a target molecule's Raman scattering signal is amplified by proximity to a plasmonic nanostructure, enabling molecular fingerprinting at trace and, in some cases, single-molecule sensitivity.
Trace evidence: physical evidence occurring in extremely small quantities, typically transferred through incidental contact, consistent with Locard's Exchange Principle.
Zeptomolar (zM): a concentration unit equal to 10⁻²¹ moles per litre, one thousand times more dilute than attomolar.
15. References
1. Carbon quantum dots (CQDs) in forensic investigations: a review of current applications and future perspectives. RSC Advances, 2025. DOI: 10.1039/D5RA05791D
2. Quantum Biosensors on Chip: A Review from Electronic and Photonic Integrated Circuits to Future Integrated Quantum Photonic Circuits. arXiv, 2025. arxiv.org/abs/2508.01663
3. Advancing biosensing and bioimaging with quantum technologies: From fundamental science to medical applications. Applied Physics Reviews, 12(3), 2025. DOI: 10.1063/5.0231311
4. Das, S., Mazumdar, H., Khondakar, K.R., Mishra, Y.K., Kaushik, A. Quantum Biosensors: Principles and Applications in Medical Diagnostics. ECS Sensors Plus, 2024. DOI: 10.1149/2754-2726/ad47e2
5. Recent Advances in Quantum Biosensing Technologies. IntechOpen, 2024. intechopen.com/chapters/1205965
6. Quantum relaxometry for detecting biomolecular interactions with single NV centers. arXiv. arxiv.org/abs/2512.10269
7. Aslam, N., Zhou, H., Urbach, E.K., et al. Quantum sensors for biomedical applications. Nature Reviews Physics, 5, 157–169, 2023. DOI: 10.1038/s42254-023-00558-3
8. High-Quality Nanodiamonds For Bioimaging And Quantum Sensing Applications. ACS Nano, December 2024, via The Quantum Insider. thequantuminsider.com
9. Recent applications of nanodiamond quantum biosensors: A review. APL Materials, 11(9), 2023. DOI: 10.1063/5.0170145
10. Forensic Detection: A Comprehensive Review of SERS Mechanisms and Applications. ACS Applied Optical Materials, 2026. DOI: 10.1021/acsaom.6c00017
11. Review of Surface Enhanced Raman Scattering Applications in Forensic Science. Analytical Chemistry. DOI: 10.1021/acs.analchem.5b04131
12. Shafirovich, T., Aligholizadeh, D., Johnson, M., Hondrogiannis, E., Devadas, M.S. Point-and-shoot: portable Raman and SERS detection of organic gunshot residue analytes. Vibrational Spectroscopy, 131, 103669, 2024. DOI: 10.1016/j.vibspec.2024.103669
13. Wongpakdee, T., Nacapricha, D., McCord, B. Modification of screen-printed electrodes using gold nanostructures for SERS detection of low explosives. Forensic Chemistry, 42, 100636, 2025. DOI: 10.1016/j.forc.2024.100636
14. Mazur, N., Dzhagan, V., Kapush, O., et al. SERS of nitro group compounds for sensing of explosives. RSC Advances, 15(1), 252–260, 2025.
15. Development of Portable Surface-Enhanced Raman Spectroscopy Nanosensors for Ultrasensitive Characterization of Drugs in Human Biofluids. National Institute of Justice / Office of Justice Programs. ojp.gov
16. Pushing Biomolecule Detection Limit With Graphene Field-effect Transistor Biosensors. Advanced Electronic Materials, 2025. DOI: 10.1002/aelm.202500368
17. Campos, R., et al. Attomolar Label-Free Detection of DNA Hybridization with Electrolyte-Gated Graphene Field-Effect Transistors. ACS Sensors, 4, 286–293, 2019. DOI: 10.1021/acssensors.8b00344
18. Hwang, M.T., Heiranian, M., Kim, Y., et al. Ultrasensitive detection of nucleic acids using deformed graphene channel field effect biosensors. Nature Communications, 11, 1543, 2020. DOI: 10.1038/s41467-020-15330-9
19. Dogan, M., Nazir, S., Jenkins, D., Wei, Y., Pan, G. Electrochemical Detection of Aβ42 and Aβ40 at Attomolar Scale via Optimised Antibody Loading on Pyr-NHS-Functionalised 3D Graphene Foam Electrodes. Biosensors, 15(12), 806, 2025. DOI: 10.3390/bios15120806
20. Sensors in the Detection of Abused Substances in Forensic Contexts: A Comprehensive Review. Micromachines, 14(12), 2249, 2023. DOI: 10.3390/mi14122249
21. CRISPR-Cas technology in forensic investigations: Principles, applications, and ethical considerations. Forensic Science International: Genetics, 2024. fsigenetics.com
22. Emerging Technologies in Forensic DNA Analysis. Perspectives in Legal and Forensic Sciences, 2024. sciepublish.com
23. Bi, X., Czajkowsky, D.M., Shao, Z., Ye, J. Digital colloid-enhanced Raman spectroscopy by single-molecule counting. Nature, 628(8009), 771–775, 2024.
24. Advances in Biosensor Technology for Illicit Drug Detection Enable Effective Wastewater Surveillance. Chem & Bio Engineering, ACS Publications, 2026. DOI: 10.1021/cbe.4c00188
EXPERT OPINION
For forensic science students and practitioners, the most useful way to think about quantum biosensors today is as an emerging research frontier that is redefining what "possible" means at the physics level — not yet a laboratory tool ready for casework. The gap between physical sensitivity and forensic-grade reliability is exactly the gap that validation science, standardisation bodies, and admissibility review exist to close, and history suggests that gap typically takes a decade or more to bridge for a genuinely new detection principle.
BEST PRACTICE
When discussing or writing about emerging forensic technologies, always distinguish explicitly between (1) an established, court-validated method, (2) an emerging technology with peer-reviewed proof-of-concept but no forensic validation, and (3) a purely experimental or theoretical capability. Blurring these categories — even unintentionally — misrepresents the state of forensic science to students, journalists, and the public.
Related Reading on Budding Forensic Expert
Explore more on Trace Evidence Examination, Locard's Exchange Principle in Modern Casework, Raman Spectroscopy in Forensic Science, DNA Profiling Fundamentals, Microplastics and DNA Evidence, Portable Forensic Instruments, Nanotechnology in Forensic Science, and Future Technologies in Crime Scene Investigation.
Conclusion: A Genuine Frontier, Not Yet a Finished Tool
The scientific consensus emerging from the 2023–2026 literature is measured rather than sensational. Quantum-enabled biosensing platforms — NV-diamond centres, quantum dots, SERS, graphene field-effect transistors, and CRISPR-hybrid systems — have genuinely demonstrated single-molecule and attomolar-to-zeptomolar sensitivity, in some cases exceeding what PCR, GC-MS, or ELISA can achieve under equivalent conditions. That is a real, peer-reviewed scientific achievement, not hype.
What these platforms have not yet achieved is forensic readiness: multi-laboratory validation, standardised reference materials, accreditation pathways, and courtroom admissibility. The practical implication for the forensic community is to treat quantum biosensing as a high-value research and future-triage direction — one worth tracking closely — while continuing to rely on validated confirmatory methods for casework until the evidence base catches up with the physics. Trace evidence examination has always advanced by absorbing better instrumentation once it is proven, not by anticipating it prematurely, and quantum biosensors appear set to follow that same disciplined path.
Continue exploring the frontier of forensic innovation — follow Budding Forensic Expert for evidence-based coverage of the technologies reshaping trace evidence examination, forensic biology, and criminal investigation.
